87 related articles for article (PubMed ID: 20420865)
1. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye.
Hagigit T; Abdulrazik M; Orucov F; Valamanesh F; Hagedorn M; Lambert G; Behar-Cohen F; Benita S
J Control Release; 2010 Aug; 145(3):297-305. PubMed ID: 20420865
[TBL] [Abstract][Full Text] [Related]
2. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
3. The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions.
Hagigit T; Nassar T; Behar-Cohen F; Lambert G; Benita S
Eur J Pharm Biopharm; 2008 Sep; 70(1):248-59. PubMed ID: 18450437
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis.
Andrieu-Soler C; Doat M; Halhal M; Keller N; Jonet L; BenEzra D; Behar-Cohen F
Mol Vis; 2006 Sep; 12():1098-107. PubMed ID: 17093395
[TBL] [Abstract][Full Text] [Related]
5. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
6. A selective method for transfection of retinal ganglion cells by retrograde transfer of antisense oligonucleotides against kynurenine aminotransferase II.
Thaler S; Rejdak R; Dietrich K; Ladewig T; Okuno E; Kocki T; Turski WA; Junemann A; Zrenner E; Schuettauf F
Mol Vis; 2006 Feb; 12():100-7. PubMed ID: 16518307
[TBL] [Abstract][Full Text] [Related]
7. Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II.
Bruxel F; Cojean S; Bochot A; Teixeira H; Bories C; Loiseau PM; Fattal E
Int J Pharm; 2011 Sep; 416(2):402-9. PubMed ID: 21291974
[TBL] [Abstract][Full Text] [Related]
8. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.
Gomes dos Santos AL; Bochot A; Doyle A; Tsapis N; Siepmann J; Siepmann F; Schmaler J; Besnard M; Behar-Cohen F; Fattal E
J Control Release; 2006 May; 112(3):369-81. PubMed ID: 16644054
[TBL] [Abstract][Full Text] [Related]
9. Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in-vivo study in rats and mice.
Hagigit T; Abdulrazik M; Valamanesh F; Behar-Cohen F; Benita S
J Control Release; 2012 Jun; 160(2):225-31. PubMed ID: 22138070
[TBL] [Abstract][Full Text] [Related]
10. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.
Khan A; Sommer W; Fuxe K; Akhtar S
J Drug Target; 2000; 8(5):319-34. PubMed ID: 11328659
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
12. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
13. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
14. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
15. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
16. Delivery of antisense oligonucleotide to the cornea by iontophoresis.
Berdugo M; Valamanesh F; Andrieu C; Klein C; Benezra D; Courtois Y; Behar-Cohen F
Antisense Nucleic Acid Drug Dev; 2003 Apr; 13(2):107-14. PubMed ID: 12804037
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
18. Hybridisation of [76Br]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR.
Wu F; Lendvai G; Yngve U; Eriksson B; Långström B; Bergström M
Nucl Med Biol; 2004 Nov; 31(8):1073-8. PubMed ID: 15607489
[TBL] [Abstract][Full Text] [Related]
19. [The effect of antisense H-ras on growth and metastasis of a high metastatic tumor model of human hepatoma in nude mice LCI-D20].
Liao Y; Tang Z; Sun F
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):650-3. PubMed ID: 9275544
[TBL] [Abstract][Full Text] [Related]
20. Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine.
Silvia CP; King GR; Lee TH; Xue ZY; Caron MG; Ellinwood EH
Mol Pharmacol; 1994 Jul; 46(1):51-7. PubMed ID: 8058056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
